NYSE:NVO - Novo Nordisk A/S Stock Price, Price Target & More

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

Novo Nordisk A/S announced a special dividend on Monday, February 5th. Stockholders of record on Monday, March 26th will be given a dividend of $0.8117 per share on Tuesday, April 3rd. This represents a dividend yield of 0.96%. The ex-dividend date of this dividend is Friday, March 23rd. View Novo Nordisk A/S's Dividend History.

Novo Nordisk A/S declared that its board has authorized a stock buyback program on Friday, February 2nd 2018, which authorizes the company to repurchase shares, according to EventVestor. This repurchase authorization authorizes the company to buy shares of its stock through open market purchases. Stock repurchase programs are generally a sign that the company's leadership believes its shares are undervalued.

Novo Nordisk A/S (NYSE:NVO) issued its quarterly earnings data on Friday, April, 29th. The company reported $0.55 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.53 by $0.02. The company earned $4.02 billion during the quarter, compared to the consensus estimate of $4.07 billion. Novo Nordisk A/S had a return on equity of 82.78% and a net margin of 35.21%. View Novo Nordisk A/S's Earnings History.

Novo Nordisk A/S is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for Novo Nordisk A/S.

Novo Nordisk A/S saw a increase in short interest in the month of April. As of April 30th, there was short interest totalling 2,147,542 shares, an increase of 53.4% from the April 13th total of 1,399,529 shares. Based on an average trading volume of 1,608,993 shares, the days-to-cover ratio is presently 1.3 days.

Some companies that are related to Novo Nordisk A/S include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), AbbVie (ABBV), Merck & Co. (MRK), Abbott Laboratories (ABT), Bayer (BAYRY), GlaxoSmithKline (GSK), Sanofi (SNY), AstraZeneca (AZN), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).

Press coverage about NVO stock has trended somewhat negative recently, Accern Sentiment reports. The research group identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Novo Nordisk A/S earned a daily sentiment score of -0.02 on Accern's scale. They also gave headlines about the company an impact score of 45.85 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Novo Nordisk A/S's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Loomis Sayles & Co. L P (0.90%), Fisher Asset Management LLC (0.54%), BlackRock Inc. (0.40%), Folketrygdfondet (0.23%), Fayez Sarofim & Co (0.19%) and Sustainable Growth Advisers LP (0.16%). View Institutional Ownership Trends for Novo Nordisk A/S.

NVO stock was sold by a variety of institutional investors in the last quarter, including Folketrygdfondet, Envestnet Asset Management Inc., Millennium Management LLC, Wells Fargo & Company MN, UBS Group AG, Hutchinson Capital Management CA, Fayez Sarofim & Co and Reynders McVeigh Capital Management LLC. View Insider Buying and Selling for Novo Nordisk A/S.

NVO stock was bought by a variety of institutional investors in the last quarter, including Loomis Sayles & Co. L P, Fisher Asset Management LLC, Carillon Tower Advisers Inc., BlackRock Inc., Assetmark Inc., Sustainable Growth Advisers LP, Twin Tree Management LP and CIBC World Markets Inc.. View Insider Buying and Selling for Novo Nordisk A/S.

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of NVO stock can currently be purchased for approximately $47.73.

Novo Nordisk A/S has a market capitalization of $117.53 billion and generates $16.96 billion in revenue each year. The company earns $5.79 billion in net income (profit) each year or $2.34 on an earnings per share basis. Novo Nordisk A/S employs 42,076 workers across the globe.

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]